newsfilter
← Latest News
GlobeNewswire·

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Announced acquisition of CT-95, a mesothelin x CD3 bispecific antibody Claudio Dansky Ullmann, M.D. named Chief Medical Officer Cash and cash equivalents of $101.5 million as of June 30, 2024 PHILADELPHIA, Aug. 07,